Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-DOTA-PEG24-Fab
- Development stage
- Preclinical
- Lead developer
- University of California, San Francisco
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
64Cu-DOTA-PEG24-Fab is a CD46-targeted radiopharmaceutical imaging agent developed by the University of California, San Francisco (UCSF) for the same-day immunoPET imaging of prostate cancer. It consists of a monovalent antigen-binding fragment (Fab) derived from the CD46-targeted monoclonal antibody YS5, conjugated to a DOTA chelator via a PEG24 linker, and radiolabeled with copper-64 (64Cu). CD46 is highly expressed in both PSMA-positive and PSMA-negative prostate cancers, making it a promising alternative target. Compared to full-length IgG-based tracers like 89Zr-DFO-YS5, which require several days to clear and achieve optimal contrast, the smaller Fab fragment clears rapidly from the blood, enabling high-contrast PET imaging just 4 hours post-injection.
- Other names
- 64Cu-DOTA-PEG24-F(ab)64Cu-DOTA-PEG24-YS5-F(ab)64Cu-DOTA-PEG24-YS5-FabCopper Cu 64-DOTA-PEG24-YS5-Fab
02
Targets
CD46 (CD46 Molecule)
Beyond the preview
Go deeper on 64Cu-DOTA-PEG24-Fab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-DOTA-PEG24-Fab.